



Real-world Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-year Results From ESTEEM

China, A., Amezcua, L., Vargas, W. *et al.* Real-World Safety and Effectiveness of Dimethyl Fumarate in Hispanic or Latino Patients with Multiple Sclerosis: 3-Year Results from ESTEEM. *Neurol Ther* (2020). <https://doi.org/10.1007/s40120-020-00192-6>



Why this study was carried out



What was learned from the study?




Figure 1: ARR in the 12 months before and 36 months after DMF initiation for the non-Hispanic/non-Latino, Hispanic/Latino, and Hispanic/Latino IFN/GA switch subgroups.

Abbreviations: annualized relapse rate (ARR); glatiramer acetate (GA); interferon (IFN); Dimethyl fumarate (DMF); multiple sclerosis (MS).